Trial of Deferiprone in Parkinson’s Disease

Devos, David; Labreuche, Julien; Rascol, Olivier; Corvol, Jean‐Christophe; Duhamel, Alain; Guyon Delannoy, Pauline; Poewe, Werner; Compta, Yaroslau; Pavese, Nicola; Růžička, Evžen; Dušek, Petr; Post, Bart; R. Bloem, Bastiaan; Berg, Daniela; Maetzler, Walter; Otto, Markus; Habert, Marie‐Odile; Lehéricy, Stéphane; J. Ferreira, Joaquim; Dodel, Richard; Tranchant, Christine; Eusébio, Alexandre; Thobois, Stéphane; Marquès, Ana; G. Meissner, Wassilios; Ory‐Magne, Fabienne; Walter, Uwe; M.A. de Bie, Rob; Gago, Miguel; Vilas, Dolores; Kulisevsky, Jaime; Januário, Cristina; Vilhena Soares Coelho, Miguel; Behnke, Stefanie; Worth, Paul; Seppi, Klaus; Ouk, Thavarak; Potey, Camille; C. Leclercq, Céline; Viard, Romain; Kuchcinski, Grégory; Lopes, Renaud; Pruvo, Jean‐Pierre; Pigny, Pascal; Garçon, Guillaume; Simonin, O.; Carpentier, Jessica; Rolland, Anne‐Sophie; Nyholm, Dag; Scherfler, Christoph; Mangin, Jean‐François; Chupin, Marie; Bordet, Régis; T. Dexter, David; Fradette, Caroline; Spino, Michael; Tricta, Fernando; Ayton, Scott; I. Bush, Ashley; Devedjian, Jean-Christophe; A. Duce, James; Cabantchik, Ioav; Defebvre, Luc; Deplanque, Dominique; Moreau, Caroline

doi:10.1056/nejmoa2209254

Public

Trial of Deferiprone in Parkinson’s Disease

Published in New England Journal of Medicine • Nov 30, 2022

Authors:

David Devos

Julien Labreuche

Olivier Rascol

Abstract

BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its e...

Subject

Deferiprone

Parkinson's disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!